Facts about the share
Novo Nordisk is a focused healthcare company. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In addition, Novo Nordisk has a leading position in areas such as haemostasis management, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
General Information
Headquarters: Denmark
International: Production facilities in 6 countries, affiliates or offices in 68 countries
Workforce: 18,756 employees (Dec. 2003). Approximately 60% of employees are located in Denmark, 35% in the rest of the world
- 19% are within research and development
- 38% in production and production administration
- 23% in international sales and marketing
- 19% in administration
The Share
Novo Nordisk's B shares are quoted on the stock exchanges in Copenhagen and London. Moreover, Novo Nordisk's ADSs are listed on the New York Stock Exchange. Please refer to the table below.
|
Stock exchange |
Listing type |
Stock symbol/name |
Reuters ticker |
|
Copen-hagen |
Listed shares |
DK001028081-7 (ISIN) |
NVOb.CO |
|
London |
Listed shares |
NVOB |
NVObq.L |
|
New York |
ADSs |
NVO |
NVO.N |
Novo Nordisk's share capital is DKK 709,388,320, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 601,901,120. Novo Nordisk's A shares are non-listed shares and held by Novo A/S (based in Gladsaxe, Denmark), a private limited Danish company which is 100% owned by the Novo Nordisk foundation (based in Gentofte, Denmark). The B shares are traded in units of DKK 2. The ratio of Novo Nordisk B shares to ADSs is 1:1. The B shares are issued to the bearer, but may upon request be registered in the holder's name in Novo Nordisk's register of shareholders. Each holding of DKK 2 of A share capital carries ten times as many votes as each holding of DKK 2 of B share capital. Each A-share carries 20 votes, whereas each B-share carries 2 votes.
|
Average number of outstanding shares end 2002 (in 1,000 shares) |
|
|
Average number of shares outstanding |
346,685 |
|
Average number of options in the money outstanding |
2,578 |
|
Average number of shares outstanding including options in the money |
349,263 |
The average number of shares outstanding is the total number of shares excluding Novo Nordisk's holding of own shares.
As Novo Nordisk B shares are in bearer form, no official record of shareholders exists. Based on the available sources of information on the company's shareholders, it is estimated that Novo Nordisk's shares at the end of 2003 were distributed as shown in the table below.
Break down of shareholders and geographical distribution of shareholders
